Monrovia, California (PressExposure) November 08, 2012 -- Howard A. Young, Principal Investigator of the Cancer and Inflammation Program at the Frederick National Laboratory for Cancer Research will give a presentation on "Host Response to Chronic Interferon-gamma Expression" at the 11th Cytokines and Inflammation Conference to be held in San Diego, CA on January 31 - February 1, 2013 by GTC.
Interferon-gamma (IFN-g) is a key player in immunoregulation, inflammation and autoimmune disease. Dr. Young's laboratory has targeted a 162nd substitution of the AU-rich element (ARE) in the 3'UTR of the IFN-g gene, resulting in chronic low levels of circulating IFN-g. The results suggest that AA occurs when IFN-y inhibits the generation of ST-HSCs from LT-HSCs, as opposed to infiltration in the bone marrow of autoreactive T cells. Overall, the data demonstrate that low chronic IFN-g levels are sufficient to alter the phenotype and potentially the development of cells important for SLE disease and aplastic anemia depending upon the genetic background of the model system.
Benefits of this presentation include:
- Demonstration on how low circulating levels of a cytokine are sufficient to trigger disease
- Discussion on how IFN-g triggers different phenotypes depending upon the host genetic background
- Demonstration on how the ARE element in the IFN-g gene is a critical determinant of mRNA stability
Dr. Young joined the National Cancer Institute in 1983 and became Deputy Chief of the NCI Laboratory of Experimental Immunology in 2006. His research has focused on the analysis of cytokine gene expression and signaling with a special emphasis on the molecular characterization of the transcriptional regulation of Interferon--ï§. Most recently, his laboratory has developed novel mouse models of lupus and aplastic anemia based on chronic expression of low levels of this important immunoregulatory molecule in the murine C57BL/6 genetic background and the Balb/c genetic background, respectively. He is also collaborating with a laboratory in Malaysia on the development of probiotic microorganisms as carriers for vaccine delivery systems.
Dr. Young is a former President of the International Society for Interferon and Cytokine Research and a co-recipient (with Dr. Sidney Pestka) of the first Distinguished Service Award from the ISICR. He is a two time recipient of the National Cancer Institute Director's Award for Mentoring also and is a recipient of the National Public Service Award from the American Society for Public Administration and the National Academy of Public Administration. He has also served as Chair of the Immunology Division of the American Society for Microbiology and is a member of the American Academy of Microbiology.
The GTC Cytokines and Inflammation conferences have become an established meeting point for academic scientists and industry clinical developers to exchange their complementary approaches in the field of cytokine biology. Participating organizations represent a great selection of innovative medical organizations from academia (City of Hope, NCI, NIH, USC, Sanford-Burnham, Cleveland Clinic, UCLA, University of Florida, etc.), industry (Amgen, Bristol-Myers Squibb, Genentech, HUMIGEN, MedImmune, Biogen Idec, Merck Serono, Novo Nordisk, etc.) and the US FDA.
This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of this track and three other concurrent tracks:
1) 5th Immunotherapeutics & Immunomonitoring
2) 2nd Allergy & Respiratory Drug Discovery
3) Immunotoxicity & Immunogenicity
For more information, please visit http://www.gtcbio.com